AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7860944 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner-supported, incentive-based educational program including special incentives (prizes) for women and their partners to participate in a breast‐feeding class and an educational series on childbirth.
Number of subjects: 68
Study 7860944 — intervention group
Group type: COMPARATOR
Intervention: Usual breast‐feeding education (control group).
Number of subjects: 68
Study 2019135 — intervention group
Group type: COMPARATOR
Intervention: Glucose alone
Number of subjects: 19
Study 2019135 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose and conventional amino acid solution
Number of subjects: 19
Study 2019135 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose and branch-chain amino acid enriched solution
Number of subjects: 19
Study 2019135 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid infusions
Number of subjects: 19
Study 2019135 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg VO2
Number of subjects: 19
Study 7046898 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine (300 mg to 2100 mg)
Number of subjects: 20
Study 7046898 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimozide (10 to 70 mg)
Number of subjects: 20
Study 31841599 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib 150 mg
Number of subjects: 75
Study 31841599 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib 300 mg
Number of subjects: 75
Study 31841599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 30169811 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate physical activity intervention
Number of subjects: 1635
Study 30169811 — intervention group
Group type: COMPARATOR
Intervention: Successful aging education control group
Number of subjects: 1635
Study 28558673 — intervention group
Group type: EXPERIMENTAL
Intervention: Geo-specific poster
Number of subjects: 752
Study 28558673 — intervention group
Group type: COMPARATOR
Intervention: Standard poster
Number of subjects: 752
Study 25142867 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS (20 Hz, 10 s, 10 trains with 80% intensity)
Number of subjects: 34
Study 25142867 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 34
Study 23252480 — intervention group
Group type: EXPERIMENTAL
Intervention: FibReORS (Apically Positioned Flap with Fibre Retention Osseous Resective Surgery)
Number of subjects: 30
Study 23252480 — intervention group
Group type: COMPARATOR
Intervention: ORS (Osseous Resective Surgery)
Number of subjects: 30
Study 23252480 — intervention group
Group type: EXPERIMENTAL
Intervention: Both FibReORS and ORS
Number of subjects: 30
Study 21211560 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyherbal formulation (Geriforte tablets)
Number of subjects: 100
Study 21211560 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 18753466 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline 8-Isoprostane (8-IsoP) levels
Number of subjects: 46
Study 18753466 — intervention group
Group type: EXPERIMENTAL
Intervention: FENO levels
Number of subjects: 46
Study 18753466 — intervention group
Group type: EXPERIMENTAL
Intervention: FEV(1)
Number of subjects: 46
Study 17114906 — intervention group
Group type: EXPERIMENTAL
Intervention: H2RB and/or PPI
Number of subjects: 62
Study 17114906 — intervention group
Group type: EXPERIMENTAL
Intervention: PA
Number of subjects: 62
Study 17114906 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study 17114906 — intervention group
Group type: EXPERIMENTAL
Intervention: PA with autoimmune thyroid disease
Number of subjects: 62
Study 17114906 — intervention group
Group type: EXPERIMENTAL
Intervention: High baseline gastrin levels
Number of subjects: 62
Study 15565751 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran
Number of subjects: 0
Study 15565751 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 0
Study 15565751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11353965 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 pneumoperitoneum cholecystectomy (PP)
Number of subjects: 15
Study 11353965 — intervention group
Group type: COMPARATOR
Intervention: Open cholecystectomy (OC)
Number of subjects: 15
Study 11353965 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic gasless cholecystectomy (AWL)
Number of subjects: 15
Study 9056163 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcidiol (32,000 IU/weekly)
Number of subjects: 40
Study 9056163 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin (100 UI/d, nasal route)
Number of subjects: 40
Study 9056163 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate (400 mg p.o./d/2 weeks/3 months)
Number of subjects: 40
Study 9056163 — intervention group
Group type: COMPARATOR
Intervention: Calcitonin and Etidronate
Number of subjects: 40
Study 8585422 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate 30 mg
Number of subjects: 21
Study 8585422 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate 60 mg
Number of subjects: 21
Study 8585422 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate 90 mg
Number of subjects: 21
Study 8585422 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate 120 mg
Number of subjects: 21
Study 8585422 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (all doses)
Number of subjects: 21
Study 2486655 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 80 micrograms in 2 ml added to 12 ml of 0.25% bupivacaine
Number of subjects: 60
Study 2486655 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 80 micrograms in 8 ml added to 12 ml of 0.25% bupivacaine
Number of subjects: 60
Study 1125699 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective vagotomy and pyloroplasty
Number of subjects: 0
Study 1125699 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly selective vagotomy
Number of subjects: 0
Study 1125699 — intervention group
Group type: COMPARATOR
Intervention: Truncal vagotomy
Number of subjects: 0
Study 1125699 — intervention group
Group type: COMPARATOR
Intervention: Selective vagotomy
Number of subjects: 0
Study 31300879 — intervention group
Group type: COMPARATOR
Intervention: Acellular dermal matrix (ADM) allograft
Number of subjects: 12
Study 31300879 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous free gingival graft (FGG)
Number of subjects: 12
Study 31300879 — intervention group
Group type: COMPARATOR
Intervention: Professional esthetic perception
Number of subjects: 12
Study 31604478 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthening exercises for the trunk, hip, and knee muscles
Number of subjects: 90
Study 31604478 — intervention group
Group type: COMPARATOR
Intervention: Strengthening exercises for the trunk, hip, and knee muscles with neuromuscular training exercises starting from the fourth week
Number of subjects: 90
Study 31604478 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular training exercises
Number of subjects: 90
Study 25567289 — intervention group
Group type: EXPERIMENTAL
Intervention: Practical approach to lung health strategy
Number of subjects: 0
Study 25567289 — intervention group
Group type: EXPERIMENTAL
Intervention: Informal healthcare provider interventions
Number of subjects: 0
Study 25567289 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 23078156 — intervention group
Group type: EXPERIMENTAL
Intervention: HBD3 peptide gel
Number of subjects: 72
Study 23078156 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide paste (CH)
Number of subjects: 72
Study 23078156 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gel (CHX)
Number of subjects: 72
Study 23078156 — intervention group
Group type: COMPARATOR
Intervention: Mismatched peptide gel (MP)
Number of subjects: 72
Study 23078156 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 72
Study 21628598 — intervention group
Group type: EXPERIMENTAL
Intervention: RI-affirmation writing task
Number of subjects: 0
Study 21628598 — intervention group
Group type: COMPARATOR
Intervention: Control writing task
Number of subjects: 0
Study 21628598 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrimination scenario
Number of subjects: 0
Study 21628598 — intervention group
Group type: COMPARATOR
Intervention: Nondiscrimination scenario
Number of subjects: 0
Study 18458163 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt tablets (200 mmol/d of sodium)
Number of subjects: 16
Study 18458163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 16540841 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (90-min bout, 80% of 12-repetition maximum)
Number of subjects: 10
Study 16540841 — intervention group
Group type: COMPARATOR
Intervention: Control (inactive)
Number of subjects: 10
Study 14507828 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin 0.75 IU
Number of subjects: 49
Study 14507828 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 49
Study 11191537 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine (10 mg/day, increased to 20 mg/day if weight regain occurred)
Number of subjects: 605
Study 11191537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 605
Study 11191537 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 605
Study 8773907 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-core ELISA
Number of subjects: 718
Study 1519781 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl (4 micrograms/kg, in 20 ml normal saline) before surgical incision, followed by epidural normal saline (20 ml) infused 15 min after incision.
Number of subjects: 30
Study 1519781 — intervention group
Group type: COMPARATOR
Intervention: Epidural normal saline (20 ml) before surgical incision, followed by epidural fentanyl (4 micrograms/kg, in 20 ml normal saline) infused 15 min after incision.
Number of subjects: 30
Study 6337610 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 0
Study 6337610 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 0
Study 29576001 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1000 mg per day)
Number of subjects: 102
Study 29576001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 30244705 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-high risk OSA group (STOP-BANG score ≥ 3)
Number of subjects: 128
Study 30244705 — intervention group
Group type: COMPARATOR
Intervention: Low-risk OSA group (STOP-BANG score < 3)
Number of subjects: 128
Study 26367217 — intervention group
Group type: COMPARATOR
Intervention: melphalan 200 mg/m² (mel200)
Number of subjects: 131
Study 26367217 — intervention group
Group type: EXPERIMENTAL
Intervention: melphalan 280 mg/m² (mel280)
Number of subjects: 131
Study 26367217 — intervention group
Group type: COMPARATOR
Intervention: mel200
Number of subjects: 131
Study 26367217 — intervention group
Group type: EXPERIMENTAL
Intervention: mel280
Number of subjects: 131
Study 24375768 — intervention group
Group type: EXPERIMENTAL
Intervention: Alisporivir (ALV) 1000 mg once-daily
Number of subjects: 249
Study 24375768 — intervention group
Group type: EXPERIMENTAL
Intervention: Alisporivir (ALV) 800 mg once-daily
Number of subjects: 249
Study 24375768 — intervention group
Group type: EXPERIMENTAL
Intervention: Alisporivir (ALV) 600 mg once-daily
Number of subjects: 249
Study 24375768 — intervention group
Group type: EXPERIMENTAL
Intervention: Alisporivir (ALV) with ribavirin (RBV)
Number of subjects: 249
Study 24375768 — intervention group
Group type: EXPERIMENTAL
Intervention: Alisporivir (ALV) 400 mg with RBV 400 mg twice-daily for 24 weeks
Number of subjects: 249
Study 24375768 — intervention group
Group type: EXPERIMENTAL
Intervention: Alisporivir (ALV) 400 mg with RBV 400 mg twice-daily for 36 weeks
Number of subjects: 249
Study 24375768 — intervention group
Group type: EXPERIMENTAL
Intervention: Response-guided treatment
Number of subjects: 249
Study 21664286 — intervention group
Group type: EXPERIMENTAL
Intervention: PBSC
Number of subjects: 0
Study 21664286 — intervention group
Group type: COMPARATOR
Intervention: BM
Number of subjects: 0
Study 19403950 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-protein beverages with casein (CAS)
Number of subjects: 10
Study 19403950 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-protein beverages with whey (WP)
Number of subjects: 10
Study 19403950 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-protein beverages with casein and whey blend (CAS-WP)
Number of subjects: 10
Study 17489483 — intervention group
Group type: EXPERIMENTAL
Intervention: Grandio (Voco)
Number of subjects: 30
Study 17489483 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek Supreme (3M ESPE)
Number of subjects: 30
Study 15673037 — intervention group
Group type: EXPERIMENTAL
Intervention: Modest training (20 trials) with visual and proprioceptive information
Number of subjects: 0
Study 15673037 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive training (720 trials) with visual and proprioceptive information
Number of subjects: 0
Study 15673037 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive information only
Number of subjects: 0
Study 12401850 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral theophylline 200 mg b.d. 24 h before and for 48 h after CAG
Number of subjects: 70
Study 12401850 — intervention group
Group type: COMPARATOR
Intervention: Routine CAG (Control group)
Number of subjects: 70
Study 9832182 — intervention group
Group type: EXPERIMENTAL
Intervention: cyclosporine (20 mg/kg body weight)
Number of subjects: 16
Study 9832182 — intervention group
Group type: COMPARATOR
Intervention: vehicle (olive oil)
Number of subjects: 16
Study 9466506 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratracheal pulmonary ventilation (ITPV)
Number of subjects: 5
Study 9466506 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation (Control)
Number of subjects: 5
Study 2792172 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous bolus of frusemide with plasma volume expansion (albumin infusion)
Number of subjects: 5
Study 2792172 — intervention group
Group type: COMPARATOR
Intervention: Intravenous bolus of frusemide without plasma volume expansion
Number of subjects: 5
Study 2792172 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of dextran
Number of subjects: 5
Study 88754 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (methotrexate 400 mg followed by citrovorum factor 100 mg + bleomycin 60 mg/week for the first 15 weeks)
Number of subjects: 95
Study 88754 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy (weekly C. parvum injections for 2 years)
Number of subjects: 95
Study 88754 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 95
Study 88754 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (Chemotherapy, Immunotherapy, No treatment)
Number of subjects: 95
Study 88754 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who previously received radiotherapy
Number of subjects: 95
Study 27872389 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intentions intervention (n=24)
Number of subjects: 50
Study 27872389 — intervention group
Group type: COMPARATOR
Intervention: Control condition based on the question‐behaviour effect (n=26)
Number of subjects: 50
Study 27872389 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intentions and question‐behaviour effect
Number of subjects: 50
Study 28864651 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee effusion-synovitis
Number of subjects: 413
Study 28864651 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline BML, cartilage defect, JSN, and osteophyte scores
Number of subjects: 413
Study 28864651 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline cartilage defects and JSN
Number of subjects: 413
Study 28864651 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in effusion-synovitis volume
Number of subjects: 413
Study 28864651 — intervention group
Group type: EXPERIMENTAL
Intervention: Effusion-synovitis
Number of subjects: 413
Study 25110303 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message intervention (approximately 3 messages per week)
Number of subjects: 87
Study 23513200 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% deproteinised bovine bone matrix (DBBM) grafts
Number of subjects: 40
Study 23513200 — intervention group
Group type: COMPARATOR
Intervention: 100% autogenous bone (AB) grafts
Number of subjects: 40
Study 21471550 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol/paracetamol (37.5+325 mg)
Number of subjects: 114
Study 21471550 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol monotherapy (1000 mg)
Number of subjects: 114
Study 19258386 — intervention group
Group type: EXPERIMENTAL
Intervention: Keto acid-supplemented low-protein diet (sLP: 0.6-0.8 g/kg IBW/day with 0.12 g/kg IBW/day of keto acids)
Number of subjects: 60
Study 19258386 — intervention group
Group type: COMPARATOR
Intervention: Low-protein diet (LP: 0.6-0.8 g/kg IBW/day)
Number of subjects: 60
Study 19258386 — intervention group
Group type: COMPARATOR
Intervention: High-protein diet (HP: 1.0-1.2 g/kg IBW/day)
Number of subjects: 60
Study 16750450 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymorphone ER 10 mg q12h
Number of subjects: 370
Study 16750450 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymorphone ER 40 mg q12h
Number of subjects: 370
Study 16750450 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymorphone ER 50 mg q12h
Number of subjects: 370
Study 16750450 — intervention group
Group type: COMPARATOR
Intervention: Placebo q12h
Number of subjects: 370
Study 15233837 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg)
Number of subjects: 33
Study 15233837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 11505046 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tryptophan depletion (concentrated amino acid drink with no tryptophan supplementation)
Number of subjects: 16
Study 11505046 — intervention group
Group type: COMPARATOR
Intervention: Placebo depletion (similar drink containing tryptophan)
Number of subjects: 16
Study 9241548 — intervention group
Group type: EXPERIMENTAL
Intervention: Various urological irrigating fluids (1,000 ml intravenous infusions)
Number of subjects: 17
Study 9241548 — intervention group
Group type: EXPERIMENTAL
Intervention: Various urological irrigating fluids
Number of subjects: 17
Study 9241548 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilutional hypocalcaemia
Number of subjects: 17
Study 8501720 — intervention group
Group type: EXPERIMENTAL
Intervention: Subzonal insemination (n = 31 oocytes)
Number of subjects: 5
Study 8501720 — intervention group
Group type: EXPERIMENTAL
Intervention: Subzonal insemination (n = 33 oocytes in second series)
Number of subjects: 5
Study 8501720 — intervention group
Group type: EXPERIMENTAL
Intervention: Subzonal insemination (n = 11 embryo transfers)
Number of subjects: 5
Study 8501720 — intervention group
Group type: COMPARATOR
Intervention: Routine IVF (n = 23 oocytes)
Number of subjects: 5
Study 3521258 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimantadine hydrochloride
Number of subjects: 145
Study 3521258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 29297732 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin (100 mg or 300 mg)
Number of subjects: 0
Study 29297732 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin (100 mg with possible increase to 300 mg)
Number of subjects: 0
Study 29297732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27300645 — intervention group
Group type: EXPERIMENTAL
Intervention: ONO-9054 30 μg/mL
Number of subjects: 21
Study 27300645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 27300645 — intervention group
Group type: EXPERIMENTAL
Intervention: ONO-9054 10 μg/mL
Number of subjects: 21
Study 27300645 — intervention group
Group type: EXPERIMENTAL
Intervention: ONO-9054 3 μg/mL
Number of subjects: 21
Study 24806568 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based intervention
Number of subjects: 210
Study 22382793 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% buffered lidocaine
Number of subjects: 256
Study 22382793 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine
Number of subjects: 256
Study 22382793 — intervention group
Group type: COMPARATOR
Intervention: bacteriostatic normal saline
Number of subjects: 256
Study 19781865 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (200mg, PO)
Number of subjects: 13
Study 19781865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 19079958 — intervention group
Group type: EXPERIMENTAL
Intervention: HP-HMG (Menopur)
Number of subjects: 0
Study 19079958 — intervention group
Group type: COMPARATOR
Intervention: rFSH (Gonal-F)
Number of subjects: 0
Study 15825071 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (titrated to reducing resting pulse by > or =25%)
Number of subjects: 62
Study 15825071 — intervention group
Group type: EXPERIMENTAL
Intervention: Banding (performed monthly until varices were eradicated)
Number of subjects: 62
Study 12425138 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound Tonsillectomy (TEuc‐group)
Number of subjects: 50
Study 12425138 — intervention group
Group type: COMPARATOR
Intervention: Conventional Tonsillectomy (TEkonv‐group)
Number of subjects: 50
Study 10369190 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone or prednisolone at 60 mg/m2 per day (up to 80 mg/day) for four to six weeks, followed by 40 mg/m2 every other day for another four to six weeks
Number of subjects: 0
Study 10369190 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone at 60 mg/m2/day (up to 80 mg/day) until urine is protein free for three days, then 40 mg/m2 every other day for another month
Number of subjects: 0
Study 10369190 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkylating agent for eight weeks
Number of subjects: 0
Study 10369190 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term, alternate-day corticosteroid
Number of subjects: 0
Study 10369190 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 0
Study 10369190 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide for 8 or 12 weeks
Number of subjects: 0
Study 10369190 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 0